| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/26/2004 | WO2003065992A3 Treating benign prostate hyperplasia with sarms |
| 02/26/2004 | WO2003057829A3 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 02/26/2004 | WO2003057144A3 Change inhibitors of dipeptidyl peptidase iv |
| 02/26/2004 | WO2003054019A3 Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| 02/26/2004 | WO2003047420A3 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| 02/26/2004 | WO2003045334A3 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| 02/26/2004 | WO2003039476A3 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 02/26/2004 | WO2003039436A3 Pharmaceutical compositions containing oxybutynin |
| 02/26/2004 | WO2003032990A3 Polymer conjugates of opioid antagonists |
| 02/26/2004 | WO2003026568A3 Androstanes as androgen receptor modulators |
| 02/26/2004 | WO2003020892A3 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
| 02/26/2004 | WO2003008449A8 Ntb-a, a surface molecule involved in natural killer cells activity |
| 02/26/2004 | WO2002103014A3 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 02/26/2004 | WO2002103002A3 Gene associated with leishmania parasite virulence |
| 02/26/2004 | WO2002099047A3 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/26/2004 | WO2002098501A3 Method and apparatus for treating tumors using low strength electric fields |
| 02/26/2004 | WO2002098424B1 Novel anti-infectives |
| 02/26/2004 | WO2002095005A3 Therapeutic dna vaccination |
| 02/26/2004 | WO2002094322A3 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
| 02/26/2004 | WO2002087411A3 Composite scaffolds and methods using same for generating complex tissue grafts |
| 02/26/2004 | WO2002083067A9 Prodrugs via acylation with cinnamate |
| 02/26/2004 | WO2002062204A3 Methods for diagnosing and treating heart disease |
| 02/26/2004 | WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof |
| 02/26/2004 | WO2002046418A3 Lipid-associated molecules |
| 02/26/2004 | WO2002046382A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | WO2002041910A8 Methods and compositions for the treatment of diseases of the eye |
| 02/26/2004 | WO2002036129A3 Topical treatment of mastalgia with arometese inhibitors such as androstendione |
| 02/26/2004 | WO2002022112A3 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 02/26/2004 | WO2002002812A3 Method for determining the susceptibility to stoke by analysing the ins gene |
| 02/26/2004 | WO2001074299A3 Compositions and methods for inhibition of cancer invasion and angiogenesis |
| 02/26/2004 | US20040040049 Reduction in the formation of the complex in the presence of the candidate agent as compared with in the absence of candidate agent indicates the candidate agent inhibits the binding of LBP-2 to the LBP-2 binding molecule |
| 02/26/2004 | US20040039298 Noninvasive measurement of chemical substances |
| 02/26/2004 | US20040039297 Noninvasive measurement of chemical substances |
| 02/26/2004 | US20040039204 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides |
| 02/26/2004 | US20040039066 Administering hydroxytyrosol and oleuropein in a ratio of 1:1-200:1 |
| 02/26/2004 | US20040039057 Putrescine, spermine, spermidine or cadaverine with urea or lidocaine |
| 02/26/2004 | US20040039055 Ameliorate the negative side effects of a serum concentration of a drug higher than that used in normal clinical practice |
| 02/26/2004 | US20040039054 Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs |
| 02/26/2004 | US20040039053 Administering to a patient a (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives or salt, free of its (+) stereoisomer to treat the type II diabetes, gout, insulin resistance and atherosclerosis |
| 02/26/2004 | US20040039041 Using an alfa2-adrenoceptor antagonist or an ester or salt selected from atipamezole, idazoxan, efaroxan or their salts, to prevent dyskinesias caused by chronic use of dopaminergic agents while treting neuropsychiatric disorders |
| 02/26/2004 | US20040039031 A combination of an antidiabetic biguanide and an antidiabetic sulfonamide, at low doses, in combination or as a mixture with inert excipient(s) |
| 02/26/2004 | US20040039018 CETP inhibitors in combination with antihypertensive agents and uses thereof |
| 02/26/2004 | US20040039016 HIV protease inhibitors |
| 02/26/2004 | US20040039010 Methods for treatment of acute lymphocytic leukemia |
| 02/26/2004 | US20040039007 Nitrogen compounds such as (6-(3-Methylaminopropyl)-2-(2-tri-fluoromethylphenyl)pyrimidin-4-yl)-(1H -pyrazolo(3,4-b)pyridin-3-yl)-amine, use as glycogen synthase kinase-3 (GSK-3) antagonists |
| 02/26/2004 | US20040038968 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione potassium salt |
| 02/26/2004 | US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 02/26/2004 | US20040038958 Topical treatment of skin diseases |
| 02/26/2004 | US20040038946 Biologically inert carrier (e.g., fullerene); a bone vector (e.g., a bisphosphonate) chemically bonded to the carrier; and a therapeutic agent chemically bonded to the carrier |
| 02/26/2004 | US20040038945 Administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound. |
| 02/26/2004 | US20040038944 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 02/26/2004 | US20040038935 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 02/26/2004 | US20040038930 Freeze drying the buffered complex, e.g., ferric hydroxide sucrose, sodium ferric gluconate or ferric saccharate, for subsequent reconstitution for parenteral injection; treating iron deficiency anemia |
| 02/26/2004 | US20040038916 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 02/26/2004 | US20040038913 Remedies for lung cancer |
| 02/26/2004 | US20040038905 Anticancer agents |
| 02/26/2004 | US20040038904 Method of treating multiple sclerosis |
| 02/26/2004 | US20040038888 Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells |
| 02/26/2004 | US20040038887 Copolymers for suppression of autoimmune diseases, and methods of use |
| 02/26/2004 | US20040038885 Carriers for administration of active principles such as drugs or nutriments, cosmetic products or plant health products such as herbicides, pesticides, insecticides, fungicides, etc. |
| 02/26/2004 | US20040038882 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038871 Attaching a linker to an amino group of the drug, the linker including an aldehyde or ketone carbonyl group, and forming an oxime by reaction of the carbonyl group with an O-alkylhydroxylamine derivative of the peptide |
| 02/26/2004 | US20040038870 Methods of drug delivery using sulphated chitinous polymers |
| 02/26/2004 | US20040038868 Administering, by way of the patient's trachea, to the target region of the patient's lung, an anti-surfactant, whereafter the target region collapses and one portion of the target region adheres to another portion of the target region |
| 02/26/2004 | US20040038863 Therapy of growth failure in an individual, comprising administering to the individual an aromatase inhibitor |
| 02/26/2004 | US20040038859 Containing stabilizing agent comprising matrix metalloproteinase inhibitor |
| 02/26/2004 | US20040038857 Treating the cell with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the cell, wherein the cell is a macrophage |
| 02/26/2004 | US20040038370 Claudin polypeptides |
| 02/26/2004 | US20040038363 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | US20040038362 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | US20040038324 Epothilone resistant cell lines |
| 02/26/2004 | US20040038297 Masp-2,a complement-fixing enzyme, and uses for it |
| 02/26/2004 | US20040038292 Comprises nucleotide sequences which code wound healing proteins for treatment and prevention of scarring, fibrosis, restenosis post angioplasty, psoriasis, benign prostatic hyperplasia, glaucoma and nervous suystem disorders |
| 02/26/2004 | US20040038275 Human frezzled-like protein |
| 02/26/2004 | US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets |
| 02/26/2004 | US20040038236 Mutation associated with epilepsy |
| 02/26/2004 | US20040037902 Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species |
| 02/26/2004 | US20040037897 Treatment of drug resistant organisms |
| 02/26/2004 | US20040037891 Storage stability at about room temperature and a pH range of 6.0-8.8; ophthalmic solution for vision defects and cleaning contact lenses; wound healing agents; antiulcer agents; antiscarring agents; bactericides; fungicides |
| 02/26/2004 | US20040037841 Nucleic acid sequences that are expressed in chondrocytes from fetal, normal, mild osteoarthritic, moderate osteoarthritic, marked and osteoarthritic |
| 02/26/2004 | US20040037836 Comprises nitroglycerin; for preventing adverse effects associated with medical device implantation; for inhibiting platelet deposition; angiotensin converting enzyme inhibitors |
| 02/26/2004 | US20040037833 Comprises purified imunoglobulin polypeptide or antigen binding fragment for diagnosis of disease/cancer |
| 02/26/2004 | US20040037829 For immunoregulation and/or treatment of inflammation; muteins |
| 02/26/2004 | US20040037826 Combined use of a modulator of CD3 and a GLP-1 compound |
| 02/26/2004 | US20040037823 Epidermal growth factors (ErbB2); comprises doxorubicin; gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037812 Flowable implantable composition comprising a support material, such as various forms of collagen or alginate beads or threads, which can support the attachment and growth of chondrocyte cells thereto, ad a method of making a flowable |
| 02/26/2004 | US20040037808 Methods for modulating T cell responses by manipulating a commom cytokine receptor gamma-chain |
| 02/26/2004 | US20040037790 An oral composition comprising: an oil extract of mastic; and an antiphlogistic. A dentrifice comprising the oral composition according to claim 1 and a gargle |
| 02/26/2004 | DE20318634U1 Topical compositions for preventing or treating rhinitis, comprising sympathomimetic agent with vasoconstrictive and/or mucosal swelling reducing action and glycosaminoglycan to reduce side-effects |
| 02/26/2004 | DE10336768A1 Medicament for improving oxygen utilization in the body, useful e.g. in combating ischemia or reperfusion damage, comprising xenon, optionally together with oxygen or nitrogen monoxide source |
| 02/26/2004 | DE10329926A1 Combination medicament, useful e.g. as anesthetic, sedative or hypnotic, comprising xenon (or gas mixture containing xenon) and dexmedetomidine |
| 02/26/2004 | DE10309368A1 Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase Pharmaceutical preparation containing RNA as a cofactor of hemostasis |
| 02/26/2004 | DE10237739A1 Inhalable medicament for treating inflammatory or obstructive respiratory diseases, containing synergistic combination of tropane derivative anticholinergic agent, corticosteroid and beta-mimetic agent |
| 02/26/2004 | CA2495956A1 Sulfonamides as potassium channel blockers |
| 02/26/2004 | CA2495452A1 Use of reboxetine for the treatment of hot flashes |
| 02/26/2004 | CA2495435A1 Nutritional supplement for adolescents |
| 02/26/2004 | CA2495185A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/26/2004 | CA2495068A1 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 02/26/2004 | CA2494687A1 Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction |